SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Shares Acquired by Schroder Investment Management Group

Schroder Investment Management Group increased its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) by 93.6% during the 4th quarter, HoldingsChannel.com reports. The firm owned 168,209 shares of the company’s stock after purchasing an additional 81,314 shares during the period. Schroder Investment Management Group’s holdings in SpringWorks Therapeutics were worth $6,113,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds have also recently added to or reduced their stakes in the business. AlphaQuest LLC boosted its holdings in shares of SpringWorks Therapeutics by 70.2% in the 4th quarter. AlphaQuest LLC now owns 1,004 shares of the company’s stock valued at $36,000 after buying an additional 414 shares during the period. KBC Group NV lifted its holdings in SpringWorks Therapeutics by 59.1% in the fourth quarter. KBC Group NV now owns 2,634 shares of the company’s stock worth $95,000 after acquiring an additional 978 shares during the last quarter. Quarry LP boosted its stake in SpringWorks Therapeutics by 20.0% in the third quarter. Quarry LP now owns 6,000 shares of the company’s stock valued at $192,000 after acquiring an additional 1,000 shares during the period. Arizona State Retirement System raised its position in shares of SpringWorks Therapeutics by 7.5% during the 4th quarter. Arizona State Retirement System now owns 17,206 shares of the company’s stock worth $622,000 after purchasing an additional 1,206 shares during the period. Finally, Venturi Wealth Management LLC bought a new stake in shares of SpringWorks Therapeutics in the 4th quarter worth approximately $45,000.

Analyst Ratings Changes

A number of research analysts recently commented on the company. HC Wainwright restated a “buy” rating and set a $74.00 price objective on shares of SpringWorks Therapeutics in a research note on Friday, February 21st. Evercore ISI upped their price target on shares of SpringWorks Therapeutics from $60.00 to $65.00 and gave the stock an “outperform” rating in a research report on Wednesday, February 12th. Guggenheim cut their price objective on shares of SpringWorks Therapeutics from $80.00 to $78.00 and set a “buy” rating on the stock in a research report on Wednesday, January 8th. Finally, Wedbush restated an “outperform” rating and issued a $81.00 target price on shares of SpringWorks Therapeutics in a research report on Thursday, February 20th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, SpringWorks Therapeutics presently has an average rating of “Buy” and an average price target of $73.20.

SpringWorks Therapeutics Stock Down 9.2 %

Shares of NASDAQ SWTX opened at $39.09 on Friday. The stock has a market cap of $2.93 billion, a P/E ratio of -11.23 and a beta of 0.79. The firm’s 50-day simple moving average is $48.71 and its 200 day simple moving average is $39.94. SpringWorks Therapeutics, Inc. has a fifty-two week low of $28.21 and a fifty-two week high of $62.00.

SpringWorks Therapeutics (NASDAQ:SWTX) last released its quarterly earnings results on Thursday, February 20th. The company reported ($1.04) EPS for the quarter, missing analysts’ consensus estimates of ($0.66) by ($0.38). The company had revenue of $61.55 million for the quarter, compared to the consensus estimate of $60.53 million. SpringWorks Therapeutics had a negative return on equity of 46.74% and a negative net margin of 134.73%. On average, sell-side analysts anticipate that SpringWorks Therapeutics, Inc. will post -2.05 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, insider Daniel Pichl sold 29,750 shares of SpringWorks Therapeutics stock in a transaction on Monday, February 10th. The stock was sold at an average price of $54.36, for a total transaction of $1,617,210.00. Following the transaction, the insider now directly owns 50,762 shares in the company, valued at approximately $2,759,422.32. This trade represents a 36.95 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, COO Badreddin Edris sold 30,000 shares of the business’s stock in a transaction on Monday, February 10th. The stock was sold at an average price of $53.13, for a total value of $1,593,900.00. Following the completion of the sale, the chief operating officer now directly owns 189,712 shares in the company, valued at $10,079,398.56. This represents a 13.65 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 440,766 shares of company stock valued at $24,402,956 over the last quarter. Corporate insiders own 7.61% of the company’s stock.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.